Analysis of claims data compared hospitalized infection rates among 11,248 matched pairs of new initiators of abatacept or TNF inhibitors. Serious hosp infections were significantly lower in ABA vs infliximab (HR 0.63; 0.47-0.85), but similar to ETN & ADA https://t.co/JhXlC7p1A7